Digital Look

Welcome to Digital Look++,
you are not logged in

PureTech Health (PRTC)

Pharma and Biotech

123.60p

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue ($m)	Pre-tax ($m)	EPS	Dividend
30-Jun-25	Interim	1.85	(43.86)	(19.00)¢	n/a

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-20	11.77	18.97	2.00¢	270.1	n/a	-99%	n/a	0.0%
31-Dec-21	17.39	(58.95)	(21.00)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-22	15.62	(92.78)	(18.00)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-23	3.33	(36.10)	(24.00)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-24	4.83	23.77	21.00¢	9.7	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-25	n/a	(144.20)	(44.36)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-26	n/a	(154.30)	(48.05)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-27	n/a	(165.30)	(51.01)p	n/a	n/a	n/a	n/a	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	273.27	8.95	47.04	0.17

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.